Brad Bolzon brings more than thirteen years of global pharmaceutical industry experience to Versant’s biotech investment team. He specializes in early stage biotech investing with a particular emphasis on new company start-ups. Prior to joining Versant, Brad served as Executive Vice President, Global Head of Business Development, Licensing & Alliances with Roche. Under his leadership, Roche’s Pharmaceuticals Division established alliances with over 75 biotech companies worldwide and significantly strengthened the company’s product pipeline. Previously, Brad held executive roles at Eli Lilly and Company in drug discovery, business development, clinical research, and regulatory affairs. Brad also serves as a board member for Amira Pharmaceuticals, Antipodean Pharmaceuticals, Sentient Pharmaceuticals, Speedel, Metabolex and is Chairman of EuroVentures, a wholly-owned start-up incubator of Versant Ventures. Brad received Doctor of Philosophy and Master of Science degrees in Pharmacology from the University of Toronto and conducted his post-doctoral research training at the Ottawa Heart Institute in Ottawa, Canada.